Latest stories on GTBP
GT Biopharma, Inc. (GTBP) Discusses TriKE Platform, Clinical Progress, and the Case for NK Cell Immunotherapy Transcript
Seeking Alpha56 · neutralproduct/pr
GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026
Business Insider56 · neutralproduct/pr
GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026
GlobeNewswire56 · neutralproduct/pr
GT Biopharma trading halted, news pending
The Fly48 · neutralgeneral
GT Biopharma Implements Reverse Stock Split, Streamlines Capital Structure
TipRanks34 · bearishgeneral
GT Biopharma, Inc. (GTBP) files 8-K
SEC 8-K50 · neutralgeneral
GT Biopharma, Inc. (GTBP) files 8-K
SEC 8-K50 · neutralgeneral
GT Biopharma reports Q2 results
Seeking Alpha34 · bearishearnings
GT Biopharma Reports Second Quarter 2026 Financial Results
GlobeNewswire50 · neutralgeneral
GT Biopharma Reports Second Quarter 2026 Financial Results
Business Insider55 · neutralgeneral
A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs
PR Newswire63 · neutralproduct/pr
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
PR Newswire67 · bullishproduct/pr
GT Biopharma Lowers Stockholder Quorum to One-Third
TipRanks50 · neutralgeneral
GT Biopharma, Inc. (GTBP) files 8-K
SEC 8-K50 · neutralgeneral
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company
PR Newswire67 · bullishproduct/pr
The $13 Million Company Teaching the Immune System to Hunt Cancer
PR Newswire63 · neutralproduct/pr
GT Biopharma reports Q1 results
Seeking Alpha34 · bearishearnings